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Abstract
Background. After EDTA-induced hypocalcaemia,
healthy volunteers treated with diltiazem display more
severe hyperparathyroidism than subjects on felodipine
studied under identical conditions. Therefore patients
with end-stage renal disease (ESRD) and severe sec-
ondary hyperparathyroidism might be particularly
sensitive to this side-effect.
Methods. To test this hypothesis, seven patients with
ESRD on chronic haemodialysis (3 women and 4 men)
with serum levels of intact PTH ranging from 204 to
675 pg/ml were studied both before and during the
first 180 min of haemodialysis against a dialysate with
low calcium concentration (0.75 mmol/1, n = 6 and
1 mmol/1, n = 1) under the following three experimental
conditions: control, felodipine (lOmg/day) and diltia-
zem (120mg b.i.d.).
Results. At onset of dialysis, plasma phosphorus level
was higher on diltiazem (2.03 ±0.08 mM) than on
felodipine (1.64±0.10, P<0.02), and on the latter
it was lower than in control condition (1.88±0.16,
P<0.02). As a probable consequence, blood ionized
calcium concentration was lower on diltiazem
(1.14 mM± 0.02, mean + SEM) than on felodipine
(1.2 ±0.03, P<0.05) or in control condition
(1.17 ±0.01, NS). There was a trend for intact PTH
to be higher on diltiazem (324±47 pg/ml) than on
felodipine (246 ±55) or in control condition (305 ±
49) and 1,25-dihydroxyvitamin D was higher indeed
on diltiazem (6.70±0.92 pg/ml) than on felodipine
(4.75 + 0.91, P<0.02) or control (3.87±0.62, P<
0.05). Area under the curve PTH over the first 60 min
of dialysis was higher by 16 ±7% on diltiazem than on
felodipine (/><0.05).
Conclusions. While on diltiazem rather than on felo-
dipine, patients with ESRD display higher plasma
phosphorus levels, and slightly aggravate the degree
of severity of hyperparathyroidism recorded during
haemodialysis against low-calcium dialysate. The long-
term effect of this new observation remains to be
evaluated.
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Professor of Medicine and Director, Policlinic of Medicine,
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Introduction
During the last decade the mechanisms governing
secondary hyperparathyroidism in patients with
chronic renal insufficiency have progressively been
elucidated. The consequences of reduction of la-
hydroxylase activity in the kidney in parallel to reduc-
tion of renal mass (diminished calcitriol production)
have been localized not only at the level of the gut
(insufficient calcium transport) and of the skeleton
(blunted sensitivity to parathyroid hormone), but also
at the level of the parathyroid gland itself (derepress-
ion of the prepro-PTH gene because of the lack of
calcitriol).
Recently the potential role of drugs, in particular
the calcium-channel blockers (CCB) to trigger second-
ary hyperparathyroidism has been addressed in several
laboratories. Barth et al., however, could not find any
significant change in serum calcium or intact PTH
levels in dialysis patients receiving nifedipine either
acutely or chronically [1]. In a study on 20 patients in
dialysis, Guerin et al. also did not find any change in
C-terminal PTH levels after 4 weeks on nicardipine
[2]. On the other hand, CCB have been shown to
modulate PTH secretion both in vitro [3-10] and in
vivo under normal conditions [5,9-12]. Recently we
demonstrated that diltiazem (but not felodipine), when
given to healthy volunteers stimulates PTH secretion,
the maximal effect being reached under hypocalcaemic
conditions [13]. Since decreased calcaemia is a common
feature of patients with chronic renal failure, this
prompted us to evaluate the impact of diltiazem and
of felodipine on parathyroid hormone secretion in
patients with end-stage renal disease both at baseline
and under haemodialysis-induced hypocalcaemia.
Subjects and methods
Seven patients (3 women, 4 men, mean age 72.5 years, range
60-82 years) on chronic haemodialysis for an average of 31
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months (12-72 months) were included in this study after
informed written consent was obtained. Predialysis serum
intact PTH levels ranged from 204 to 675 pg/ml (normal
10-65 pg/ml). At time of Inclusion, four patients were treated
with CCB (nifedipine n = 2, amlodipine n = 2) because of
hypertension, none of the patients received vitamin D derivat-
ives or aluminum-containing phosphate binders, and calcium
carbonate was the sole phosphate binder given. The latter
was kept unchanged throughout the study. Patients were
instructed to keep dietary phosphorus intake constant while
participating in the trial.
All patients were studied under three experimental condi-
tions: after a minimum of 2 weeks without any CCB, after
2 weeks on felodipine (lOmg/day), and after 2 weeks on
diltiazem (120 mg b.i.d.). A washout period of 2 weeks was
inserted between the two treatment regimens. Patients not
previously treated with nifedipine or amlodipine were studied
untreated first (n = 3), then on felodipine, and then on
diltiazem. In the other patients, nifedipine or amlodipine was
discontinued and replaced first by felodipine {n = 2) or diltia-
zem (n = 2); thereafter they received the crossed-over CCB
and were finally studied in the control condition.
On all three experimental settings, patients were investi-
gated in the morning under fasting condition, during the first
180 min of a 3-4 h dialysis session carried out with a
cuprophane membrane at a flow rate of 250-450 ml/min. To
induce hypocalcaemia, a dialysis fluid with low calcium
concentration was used (0.75 mmol/1, n = 6 and 1 mmol/1,
n = l ) . For a given patient, dialysis parameters were kept
identical on each of the three treatment conditions. Blood
pressure was recorded at the start of the dialysis session. At
times 0, 15, 30, 45, 60, 90, 120, 150 and 180 min, blood was
drawn from the arterial outlet of the fistula for measurement
of the concentrations of ionized calcium, inorganic phos-
phorus, magnesium, intact PTH, and vitamin D metabolites
(the latter at times 0 and 180 min only). Basal values were
also obtained for glucose and insulin concentrations.
Ionized calcium was measured in whole blood at bedside
with an ion-selective electrode (ionized Ca/pH analyser #634,
Ciba Corning Diagnostica AG, Switzerland, normal range
1.15-1.30 mmol/1 at pH 7.4). For other assays, blood was
centrifuged and frozen at — 20°C. Plasma inorganic phos-
phorus, magnesium and glucose were measured using
standard techniques in the central laboratory at our Inst-
itution (normal range 0.74-1.55 mmol/1 for phosphorus,
0.70-0.95 mmol/1 for magnesium, and 3.66-5.55 mmol/1 for
glucose). Intact PTH was measured in serum by immunoradi-
ometry, using two antibodies (Allegro, Nichols Institute, San
Juan Capistrano, CA; normal range 10-65 pg/ml, detection
limit lpg/ml). Serum 25(OH)D3 and 1-25(OH)2D3 were
assayed with a commercial kit (Nichols Institute, normal
range 6—40 ng/ml and 25-79 pg/ml respectively). Insulin was
measured in plasma by radioimmunoassay (Pharmacia
Biotech Europe, Brussels, Belgium) (normal range 4—30
mU/1).
Results at different times during the haemodialysis session
were expressed as means ± SEM of absolute values as well
as of percentage change from control condition. Statistical
analysis was performed with ANOVA for repeated measure-
ments and Wilcoxon signed-rank test.
Results
Baseline values (Table 1 [t0], Figure 1)
Systolic blood pressure was lower under both CCB
treatments than under control condition, with no
difference between the CCB treatment periods.
On diltiazem there was a tendency for blood ionized
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Table 1. Mean values ± SEM at baseline and after 180 min of
haemodialysis co, control; fdp, felodipine; dtz, diltiazem
BP syst (mmHg)
BP diast (mmHg)
C a + + (mM)
Mg(mM)
P(mM)
PTH (pg/ml)
25-<OH)D3 (ng/ml)
l,25-(OH)j D3 (pg/ml)
t
(
CO
fdp
dtz
CO
fdp
dtz
CO
fdp
dtz
CO
fdp
dtz
CO
fdp
dtz :
CO
fdp
dtz
CO
fdp
dtz :
CO .
fdp '
dtz (
0
mean ± SEM)
156±8
138±8*
142±9*
83±5
81±3
80±5
.17±0.01
.20 ±0.03
.14±0.02t
.22 ±0.04
.23 ±0.00
.25 ±0.04
.88±0.16
.64±0.10**
>.03±O.O8t
305 ±49
246 ±55
324 ±47
8.3±2.3
8.1 ±2.2
W.I ±3.1
3.87 ±0.62
1.75 ±0.91
5.70±O.92*{
tl80
(mean ± SEM)
133±9
124±4
119±8
72±4
68±3
75±4
0.97 ±0.03
0.95 ±0.02
0.94 ±0.04
1.12±0.02
1.17±0.04
1.14±0.03
0.76±0.06
0.72 ±0.02
0.72 ±0.09
540±88
550 ±96
569 ±107
18.6±2.0
18.2±2.0
20.0 ±2.9
5.00 ±0.43
6.65 ±1.64
6.16 ±0.76
P
0.04
NS
0.04
0.03
0.02
NS
0.02
0.02
0.02
0.03
NS
0.03
0.02
0.02
0.02
0.02
0.02
0.02
NS
NS
NS
NS
NS
NS
•P<0.05 vs co, t^<0.05 vs fdp.
**/><0.02 vs co, \P<0.Ci2 vs fdp (Wilcoxon signed rank test).
calcium concentration to be lower (P=0.09, ns) and
for intact PTH level to be higher (/> = 0.39, NS) than
under control condition; on felodipine, inverse trends
were observed. None of these differences, however,
reached statistical significance, whereas blood ionized
calcium concentration was significantly lower on diltia-
zem than on felodipine (/"<0.05). It has to be noted,
however, that after exclusion of one outlier with par-
ticularly high intact PTH levels at the beginning of the
study (Figure 1, patient B), the difference between
PTH levels under felodipine and those under diltiazem
were statistically significant (/>=0.03).
In all patients, 25(OH)D3 serum levels were within
the normal range, without difference among the three
groups. In all patients, 1,25(OH)2D3 serum concentra-
tions were below the normal range; under diltiazem;
however, mean value was significantly higher than on
the other two regimens (P<0.05 vs control; P<0.02
vs felodipine). Plasma magnesium concentrations were
above the normal range in all patients, and so were
plasma phosphorus levels in five patients of seven. In
the seven patients plasma phosphorus concentration
on diltiazem (dtz) was higher than on felodipine (fdp)
(P<0.02) and the latter was lower than in control (co)
condition (P<0.02). Serum concentrations of glucose
(co, 4.63±0.18mM; fdp, 4.86±0.40; dtz, 4.66±0.17)
and of insulin (co, 10.94 ± 2.97 mU/1; fdp, 14.11 ±4.50;
dtz, 10.00 ±2.25) were identical in the three treatment
conditions. Moreover, none of the treatments altered
the correlation serum glucose vs insulin levels (_y =
0.059 + 4.030, n = 2\, r2=0.546, ^ = 0.0043).
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Fig. 1. Individual concentrations of plasma phosphorus, whole
blood ionized calcium, and serum intact PTH obtained after 2 weeks
under three different experimental conditions: no calcium channel
blockers (control), felodipine, or diltiazem. *After exclusion of
patient B.
Relevant values after 180 min on dialysis (Table 1, t18a)
As a consequence of haemodialysis, plasma phos-
phorus concentrations decreased dramatically below
the normal range in all three experimental groups (P=
0.02). Plasma magnesium concentrations decreased
slightly both under control condition and on diltiazem
(^=0.03) but not on felodipine; however, all post-
dialysis values remained over the normal range.
Changes in plasma phosphorus, blood ionized calcium,
and serum intact PTH levels over dialysis time
Comparison of plasma phosphorus profiles (ANOVA
for repeated measurements of the nine time points
from 0 to 180 min) during haemodialysis revealed
—r—
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Fig. 2. Serum intact PTH concentrations on felodipine (A) or
diltiazem (A) at different times of a haemodialysis session using a
low-calcium bath. Results given as % of values obtained without
CCB treatment. Felodipine vs control, P = 0A (for all time points);
P = 0.016 (for time points 0-120); diltiazem vs control, /> = 0.043;
diltiazem vs felodipine, P = 0.0001 (ANOVA for repeated measure-
ments for all time points).
higher values while patients were on diltiazem com-
pared with felodipine (P<0.001), and lower ones while
they were on felodipine compared with control condi-
tion (P<0.001), the latter curve being intermediate.
However, initial differences in mean plasma phos-
phorus concentration gradually levelled off over
haemodialysis time, being no longer statistically differ-
ent from each other after the dialysis session.
Similarly, blood ionized calcium concentrations fell
during haemodialysis under all experimental condi-
tions. Taking all time points together, blood ionized
calcium concentration was higher on felodipine than
on diltiazem (P< 0.001) or under control condition
(P<0.05), whereas it was lower on diltiazem compared
with control condition (P< 0.001). Again, over haemo-
dialysis time, all differences progressively vanished.
Changes in intact PTH serum concentrations were
a mirror image of those of blood calcium (Figure 2).
Again, taking all time points together, intact PTH
levels were higher on diltiazem than on felodipine
(/><0.001) and under control condition (P<0.05), and
considering only time points 0-120 min, they were
lower on felodipine than without any of these drugs
(P<0.02).
Integrated parathyroid secretion over the first 60
min on dialysis can be represented by the area under
the curve (AUC) of PTH/time. In six of the seven
patients, AUC was higher on diltiazem than on felodip-
ine, the mean difference being 16 + 7% (/><0.05).
PTH/Ca concentrations relationship
Figure 3 depicts the PTH/Ca response curves on the
three experimental conditions: it is apparent that these
relationships were virtually identical. In the absence of
induced hypercalcaemia in this study, the calcium set
points could not be calculated from these data, since
in most cases baseline PTH concentrations were over
50% of maximal values.
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Fig. 3. Relationship between serum intact PTH and blood ionized
calcium concentrations during a haemodialysis session using low-
calcium bath in seven patients receiving no CCB (O), felodipine
(A) or diltiazem (A).
Discussion
The present study shows that patients with end-stage
renal disease (ESRD) who are treated with CCB have
higher (P<0.02) plasma phosphorus concentrations
on diltiazem than on felodipine, and lower ones
(P<0.02) on felodipine than without any of these
drugs. As a probable consequence of this, there were
changes in blood ionized calcium levels which were
lower on diltiazem than on felodipine as well as changes
in serum PTH and 1,25 (OH)2D concentrations, which
were higher on diltiazem than on felodipine. However,
maximal PTH concentrations under haemodialysis-
induced hypocalcaemia were not significantly different
under both treatment conditions, although the areas
under the curves of the relationships serum PTH
concentration over time were 16% higher on diltiazem
than on felodipine (/><0.05).
These results are in keeping with those recently
obtained in healthy volunteers during EDTA-induced
hypocalcaemia, which also showed more marked
hyperparathyroidism on diltiazem than on felodipine
[13]. In these subjects, however, maximal PTH concen-
trations under EDTA-induced hypocalcaemia were cle-
arly higher on diltiazem than on felodipine.
Several explanations may be provided to account
for this difference. Firstly, one has to realize that the
levels of PTH reached at any time point by the ESRD
patients of the present study are almost by one order
of magnitude higher than those reached by the healthy
subjects, i.e. a tremendously higher background noise.
For PTH values ranging from 500 to 700 pg/ml, rela-
tively small differences in PTH for a given blood level
of calcium cannot be expected to be detected in a
population of seven ESRD patients, whereas within
the range of PTH values obtained in normal subjects,
such was possible between the diltiazem and the felodi-
pine condition. Actually, after exclusion of one patient
with particularly high intact PTH serum concentra-
tions, mean PTH serum level was significantly higher
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(/><0.05) after treatment with diltiazem rather than
with felodipine. Secondly, whereas hypocalcaemia
induced by EDTA is a relatively pure disorder (with
the exception of concomitant chelation of serum mag-
nesium), hypocalcaemia induced by low-calcium
haemodialysis is accompanied by a host of disturbances
such as the changes in acid-base status, urea, phos-
phorus, and to a lesser extent magnesium concentra-
tions, which may at least in part act independently on
the Ca-PTH secretory axis. Thirdly, parathyroid hor-
mone may be cleared by the haemodialysis process,
especially when using polyacrylonitrile membranes;
however, the clearance of intact PTH appears to be
very small when using cuprophane membranes similar
to those used in the present study [14].
Beyond the speculations around differences between
both studies, two aspects of the observation in ESRD
patients deserve special mention. One is technical and
deals with the progressive reduction of the differences
in plasma phosphorus, in blood ionized calcium as
well as in serum intact PTH levels between the two
treatment phases and the control conditions over the
time course of the haemodialysis session, i.e. after 60
min: it reflects progressive equilibration between blood
and dialysate compartments as well as clearance of the
drug through the dialysis membrane. The other one
deals with the apparent disturbance of phosphorus
homeostasis in ESRD patients treated with CCB.
Clearly, ESRD patients on diltiazem have higher
plasma phosphorus concentrations than on felodipine
and lower ones on felodipine than without these drugs.
What is the reason for this?
The obvious explanation to consider first is non-
compliance to the diet in an ambulatory setting.
However, this view cannot hold if one remembers that
the patients were randomly assigned to a sequence
diltiazem-felodipine vs felodipine-diltiazem and that
seven of seven patients had a higher plasma phos-
phorus concentration on diltiazem than on felodipine,
a difference by about 25% on average.
In healthy volunteers CCB (e.g. verapamil) have not
been shown to lead to any specific effect on serum
concentrations of phosphate [15] and our previous
studies on diltiazem and felodipine [13] have confirmed
this point1. Under pathological conditions there is
some evidence for direct interactions between CCB
and phosphorus metabolism, but they are scarce. For
instance, the protective effect of CCB against ischaemic
damage has been associated with delayed cellular deple-
tion of high-energy phosphate, be it in the brain with
nimodipine [16], in the myocardium with nifedipine
[17] and verapamil [ 18] or in the kidney with verapamil
[19]. Such intracellular accumulations of phosphorus
could not account for increments in plasma levels as
observed with diltiazem, but could theoretically be
invoked to decrements in plasma phosphorus levels
* Data on phosphorus were not reported in the paper. At baseline
they were as follows: 1.23 ± 0.075 mM on diltiazem, vs
1.26 ± 0.094 mM on felodipine and 1.20 ± 0.056 mM on control
condition (/) = ns).
74
after felodipine. As an alternative it is known that
CCB, like nifedipine and verapamil, can amplify the
stimulatory action of insulin on cellular uptake of
phosphate [20]. Again, this mechanism could not
account for the data on diltiazem, but maybe for those
on felodipine. However, a direct effect of diltiazem or
of felodipine on basal insulin secretion has been reason-
ably excluded in the present study by the identical
serum levels of glucose and insulin in both treatment
conditions.
Verapamil has been shown to increase serum phos-
phate as well as urinary excretion rate of phosphate
in patients with post-surgical hypoparathyroidism
[21]: the mechanism postulated by the authors is a sti-
mulation of bone resorption. However, in the present
study a direct effect of CCB on bone would be hard
to reconcile with the data on calcium and PTH
concentrations.
Another explanation for differences in plasma phos-
phorus concentrations might be the different side-
effects of the two CCBs: nausea has been reported in
patients under diltiazem, whereas it is rarely seen in
patients under felodipine. However, since none of
our patients reported nausea, this explanation is rather
unlikely.
Therefore we are probably left with two possibilities
which, to the best of our knowledge, have not been
addressed so far: either a non-insulin-dependent drug-
induced shift of the equilibrium between intra- and
extracellular phosphorus, or an effect of CCB on
intestinal transport of phosphate, with opposite actions
of diltiazem and felodipine which ESRD unmasks.
Whatever the mechanism, the present study confirms
in patients with ESRD the trend for relative hyperpara-
thyroidism on diltiazem versus felodipine previously
noted in healthy volunteers [13], although the magni-
tude of the effect appears to be smaller in the former
subjects than in the latter. Both drugs seem to affect
the control of plasma phosphorus levels, which might
thus require increments in the doses of phosphate
binders while on diltiazem. Long-term studies on a
larger population of such patients are needed, how-
ever, to evaluate the clinical significance of this new
observation.
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